Maravai LifeSciencesReleases 2024 Sustainability Report
Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.
The report details strong employee engagement with a 95% survey participation rate and expanded employee resource initiatives. In governance, the company appointed R. Andrew Eckert as independent Chairman and strengthened its intellectual property position. Sustainability efforts included enhanced greenhouse gas emissions reporting, solar energy generation at the Leland facility, and EV charging stations that saved over 19,000 gallons of gasoline.
Maravai LifeSciences (NASDAQ: MRVI) ha pubblicato il suo Rapporto di Sostenibilità 2024, evidenziando importanti progressi in quattro aree chiave: Innovazione di Prodotto, Persone, Governance e Crescita Sostenibile. L'azienda ha lanciato 49 nuovi prodotti e ha completato una struttura GMP all'avanguardia a San Diego, aumentando di dieci volte la capacità di produzione di mRNA. Tra i risultati più rilevanti c'è la creazione di un Centro di Innovazione per l'RNA in collaborazione con la Johns Hopkins University e la produzione di oltre 130 lotti GMP di mRNA.
Il rapporto evidenzia un forte coinvolgimento dei dipendenti con un tasso di partecipazione al sondaggio del 95% e l'espansione delle iniziative di risorse per i dipendenti. Sul fronte della governance, l'azienda ha nominato R. Andrew Eckert come Presidente indipendente e ha rafforzato la sua posizione in materia di proprietà intellettuale. Gli sforzi per la sostenibilità includono un miglioramento nella rendicontazione delle emissioni di gas serra, la generazione di energia solare presso la struttura di Leland e stazioni di ricarica per veicoli elettrici che hanno consentito un risparmio di oltre 19.000 galloni di benzina.
Maravai LifeSciences (NASDAQ: MRVI) ha publicado su Informe de Sostenibilidad 2024, destacando avances significativos en cuatro áreas clave: Innovación de Producto, Personas, Gobernanza y Crecimiento Sostenible. La empresa lanzó 49 nuevos productos y completó una instalación GMP de última generación en San Diego, aumentando la capacidad de producción de ARNm diez veces. Logros destacados incluyen establecer un Centro de Innovación en ARN con la Universidad Johns Hopkins y fabricar más de 130 lotes GMP de ARNm.
El informe detalla una fuerte participación de los empleados con una tasa de respuesta del 95% en la encuesta y la expansión de iniciativas de recursos para empleados. En gobernanza, la empresa nombró a R. Andrew Eckert como presidente independiente y fortaleció su posición en propiedad intelectual. Los esfuerzos de sostenibilidad incluyeron una mejora en la presentación de informes de emisiones de gases de efecto invernadero, generación de energía solar en la planta de Leland y estaciones de carga para vehículos eléctricos que ahorraron más de 19,000 galones de gasolina.
Maravai LifeSciences(NASDAQ: MRVI)는 2024년 지속 가능성 보고서를 발표하며 제품 혁신, 인력, 거버넌스, 지속 가능한 성장의 네 가지 주요 분야에서 중요한 진전을 강조했습니다. 회사는 49개의 신제품을 출시했으며 샌디에이고에 최신 GMP 시설을 완공하여 mRNA 생산 능력을 10배로 늘렸습니다. 주요 성과로는 존스 홉킨스 대학과 함께 RNA 혁신 센터를 설립하고 mRNA GMP 배치 130개 이상을 생산한 것이 있습니다.
보고서는 95%의 설문 참여율을 기록한 강력한 직원 참여와 확대된 직원 자원 이니셔티브를 자세히 설명합니다. 거버넌스 측면에서는 R. Andrew Eckert를 독립 이사회 의장으로 임명하고 지적 재산권 위치를 강화했습니다. 지속 가능성 노력에는 온실가스 배출 보고 강화, 리랜드 시설의 태양광 에너지 생성, 19,000갤런 이상의 휘발유 절약을 이끈 전기차 충전소 설치가 포함됩니다.
Maravai LifeSciences (NASDAQ : MRVI) a publié son rapport de durabilité 2024, mettant en lumière des progrès significatifs dans quatre domaines clés : innovation produit, personnel, gouvernance et croissance durable. L'entreprise a lancé 49 nouveaux produits et a achevé une installation GMP ultramoderne à San Diego, augmentant la capacité de production d'ARNm par dix. Parmi les réalisations notables figurent la création d'un centre d'innovation en ARN avec l'université Johns Hopkins et la fabrication de plus de 130 lots GMP d'ARNm.
Le rapport détaille un fort engagement des employés avec un taux de participation de 95 % à l'enquête et l'expansion des initiatives en ressources humaines. En matière de gouvernance, la société a nommé R. Andrew Eckert président indépendant et renforcé sa position en propriété intellectuelle. Les efforts en matière de durabilité incluent une meilleure déclaration des émissions de gaz à effet de serre, la production d'énergie solaire sur le site de Leland et des bornes de recharge pour véhicules électriques qui ont permis d'économiser plus de 19 000 gallons d'essence.
Maravai LifeSciences (NASDAQ: MRVI) hat seinen Nachhaltigkeitsbericht 2024 veröffentlicht und dabei bedeutende Fortschritte in vier Schlüsselbereichen hervorgehoben: Produktinnovation, Mitarbeiter, Governance und nachhaltiges Wachstum. Das Unternehmen brachte 49 neue Produkte auf den Markt und fertigte eine hochmoderne GMP-Anlage in San Diego fertig, wodurch die mRNA-Produktionskapazität verzehnfacht wurde. Zu den bemerkenswerten Erfolgen gehört die Einrichtung eines RNA-Innovationszentrums in Zusammenarbeit mit der Johns Hopkins University sowie die Herstellung von über 130 GMP-Chargen für mRNA.
Der Bericht beschreibt eine starke Mitarbeiterbeteiligung mit einer Umfrageteilnahme von 95 % und erweiterte Initiativen für Mitarbeiterressourcen. Im Bereich Governance ernannte das Unternehmen R. Andrew Eckert zum unabhängigen Vorsitzenden und stärkte seine Position im Bereich geistiges Eigentum. Die Nachhaltigkeitsmaßnahmen umfassten eine verbesserte Berichterstattung über Treibhausgasemissionen, Solarenergieerzeugung am Standort Leland sowie Ladestationen für Elektrofahrzeuge, die über 19.000 Gallonen Benzin einsparen konnten.
- Launched 49 new products including CleanCap® M6 analog at GMP quality
- Increased mRNA production capacity tenfold with new GMP facility in San Diego
- Established RNA Innovation Center partnership with Johns Hopkins University
- Achieved 95% employee engagement survey participation rate
- Strengthened IP position with additional CleanCap® patents in China and Canada
- None.
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth
Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives
Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company’s Sustainability webpage (investors.maravai.com/sustainability). The new report highlights progress during calendar year 2024 across Maravai’s four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company’s commitment to sustainable value creation.
“By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,” said Trey Martin, Chief Executive Officer. “Our 2024 achievements position Maravai to remain our customers’ first choice as they advance their programs in next-generation therapeutics and diagnostics.”
Key highlights from the 2024 report include:
Product Innovation
- Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality
- Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold
- Established RNA Innovation Center in collaboration with Johns Hopkins University
- Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA
Our People
- Achieved
95% participation rate in our annual employee engagement survey, receiving over 2,600 comments - Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization
- Implemented new career framework creating transparent progression paths for all employees
- Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours
Governance
- Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board
- Adopted formal, publicly available Human Rights Policy
100% of standing Board Committees chaired by independent members- Strengthened intellectual property position with additional CleanCap® patents in China and Canada
Sustainable Growth
- Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting
- Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately
20% of facility's energy use - San Diego EV charging stations helped save over 19,000 gallons of gasoline
- Advanced planning for lab plastics recycling program and single-use plastic phase-out
The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs).
About Maravai
Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai’s most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law.
Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@maravai.com
FAQ
What are the key achievements in Maravai LifeSciences (MRVI) 2024 Sustainability Report?
How has Maravai LifeSciences (MRVI) improved its manufacturing capacity in 2024?
What sustainability initiatives did Maravai LifeSciences (MRVI) implement in 2024?
What governance changes did Maravai LifeSciences (MRVI) make in 2024?
